HPR44 Evolving PICO Characteristics in the Early Oncology Treatment Lifecycle: Differences from Trials to Treatment Guidelines

Abstract

Under the new European health technology assessment (HTA) legislation, European countries will largely need to agree on the PICO (population, intervention, comparator, outcome) elements in HTA assessments. Additionally, cross-stakeholder alignment grows in importance due to our ever-evolving healthcare landscape, such as smaller populations and increasingly advanced products. The PICO therefore becomes more subject to variation among decision-makers. This study assessed how the PICO elements evolve over the early treatment lifecycle of oncology drugs and align between stakeholders on a global level.